Aaron Andrew Fletcher

Mr. Aaron Andrew Fletcher

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
AFAaron Andrew Fletcher
Aaron Andrew Fletcher
JDJared Christian Durieux
Jared Christian Durieux
IBIlya Bederman
Ilya Bederman
JFJohn Feczko
John Feczko
OAOrnina Atieh
Ornina Atieh
GMGrace A McComsey
Grace A McComsey
Background: Recently, elevated levels of plasma erythritol have been associated with major adverse cardiovascular events (MACE). It is known that people with HIV (PWH) have a higher cardiovascular disease burden. Whether PWH have higher levels of plasma erythritol has not been evaluated. This study aimed to assess if blood erythritol levels are elevated in PWH and to examine relationships between erythritol and dietary, cardiometabolic, inflammatory, and gut health markers. Methods: Plasma erythritol levels were measured using frozen samples from 162 participants, including 109 PWH and 53 people without HIV (PWoH) in a parent study. General linear models were used to assess the linear relationship between characteristics, cardiovascular measures, markers of body composition, inflammation, and gut integrity with plasma erythritol. Logistic regression was used to assess risk factors associated with PWH, and cumulative logit models were used to investigate which factors were associated with having the highest plasma erythritol levels among PWH. Results: Compared to PWoH, PWH had higher plasma erythritol levels (p = 0.03). Every 10% increase in VLDL (p = 0.01), visceral adipose tissue (p < 0.0001), or TNFrI (p = 0.01) was associated with an approximately 1% increase in plasma erythritol. Among PWH, HgbA1c (p = 0.003), TNFrI (p = 0.002), and IFAB-P (p = 0.004) were associated with having the highest tertile of plasma erythritol (≥3.6 μM). Compared to PWoH, PWH were more than two times as likely (p = 0.03) to have plasma erythritol ≥ 3.6 μM. Conclusions: We identified positive associations between plasma erythritol levels and several factors, including HIV status, BMI, adipose tissue, TNFr1, HbA1c, and VLDL. These results underscore the importance of further investigating the role of elevated plasma erythritol levels in people with HIV, particularly in light of their increased vulnerability to cardiovascular and metabolic diseases.

17 July 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
AFAaron Andrew Fletcher
Aaron Andrew Fletcher
ZKZiad Koberssy
Ziad Koberssy
JDJoviane Daher
Joviane Daher
NMNicolas Moussallem
Nicolas Moussallem
GMGrace A. McComsey
Grace A. McComsey
People living with HIV (PWH) experience ongoing systemic inflammation driven by gut dysbiosis, epithelial barrier disruption, and microbial translocation, despite antiretroviral therapy (ART). This review examines evidence from randomized controlled trials, mechanistic studies, systematic reviews, and meta-analyses evaluating nutritional and microbiome-based interventions to reduce inflammation in PWH. Reduced production of short-chain fatty acids (SCFAs) by the gut microbiota has been observed to precede morbidity and mortality in PWH, with SCFAs, mainly butyrate, exerting immunomodulatory effects through promoting regulatory T-cell differentiation via histone deacetylase inhibition and G protein-coupled receptor 43 (GPR43) and GPR109A signaling, suppressing nuclear factor kappa B (NF-κB)-mediated pro-inflammatory cytokine production, and enhancing epithelial tight junction integrity. Probiotics, prebiotics, synbiotics, and fecal microbiota transplantation have demonstrated reductions in inflammatory biomarkers including soluble CD14 (sCD14), lipopolysaccharide-binding protein (LBP), and high-sensitivity C-reactive protein (hsCRP). The Mediterranean diet, omega-3 fatty acids, and polyphenol-rich foods represent an underexplored area as modulators of gut microbiota composition and SCFA production. Existing gaps in the literature include a lack of trials with clinically meaningful endpoints, optimal probiotic strains and doses, and lack of randomized trials evaluating anti-inflammatory dietary patterns in PWH. We propose a research agenda prioritizing Mediterranean diet intervention trials, precision microbiome interventions, and combination approaches integrating dietary modification with microbiome-targeted therapies. Lastly, we provide practical nutritional recommendations for clinicians managing PWH.

29 September 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
RARuth O Adekunle
Ruth O Adekunle
QWQian Wu
Qian Wu
ASAbdus Sattar
Abdus Sattar
KAKianoush Ansari-Gilani
Kianoush Ansari-Gilani
DLDanielle Labbato
Danielle Labbato
AEAllison Ross Eckard
Allison Ross Eckard
Background: Human immunodeficiency virus (HIV)–associated lipohypertrophy is characterized by excess central and visceral adiposity and is associated with increased cardiometabolic risk among people with HIV (PWH). In a previously reported randomized trial, semaglutide significantly reduced body weight, regional adiposity, and insulin resistance over 32 weeks of active treatment. However, the durability of these benefits after treatment discontinuation is unknown. Methods: We conducted a randomized, placebo-controlled trial in PWH with HIV-associated lipohypertrophy. Participants were randomized to semaglutide or placebo for 32 weeks, followed by discontinuation of study drug and observational follow-up through week 56. The current analysis investigated effects of semaglutide at week 56, as compared to baseline and week 32. Outcomes included adipose tissue quantity by body compartment. Analyses were performed using intention-to-treat principles. This trial was registered at ClinicalTrials.gov (NCT04019197) and is complete. Results: Of 108 participants initially randomized, 92 completed the 32-week intervention and 80 participants (39 semaglutide, 41 placebo) completed the posttreatment phase. Participants previously assigned to semaglutide experienced increases in body weight, body mass index (BMI), waist circumference, total body fat, and visceral adipose tissue between weeks 32 and 56, accompanied by worsening glycemic indices and insulin resistance. Despite this rebound, net reductions in body weight, BMI, and waist circumference were retained at week 56 compared with baseline. Placebo-treated participants demonstrated relative stability across outcomes. Conclusions: Discontinuation of semaglutide in PWH with lipohypertrophy resulted in partial loss of improvements in weight, adiposity, and metabolic parameters. These findings support that sustained pharmacologic exposure is likely needed to achieve long-term benefit.

11 April 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
ZKZiad Koberssy
Ziad Koberssy
AFAaron Andrew Fletcher
Aaron Andrew Fletcher
JDJoviane Daher
Joviane Daher
JMJennifer E. Murphy
Jennifer E. Murphy
JBJhony Baissary
Jhony Baissary
GMGrace A McComsey
Grace A McComsey
Background/Objectives: People with HIV (PWH) remain at high risk for cardiovascular and metabolic complications despite effective antiretroviral therapy (ART). Diet quality is an important modifiable factor that may influence these complications. Diets high in ultra-processed foods (UPF) have been linked to adverse metabolic and inflammatory profiles in the general population, but their impact on PWH remains poorly understood. The NOVA 4 classification categorizes foods by degree of processing, from unprocessed/minimally processed (NOVA 1) to UPF (NOVA 4). Methods: We conducted a cross-sectional study of adults with virologically suppressed HIV on stable ART. Assessments included dietary intake consisting of 24 h recalls analyzed with Nutrition Data System for Research software (NDSR) and classified into NOVA categories by a registered dietitian and the following characteristics: body composition (total and regional fat by DEXA and CT scan abdomen), cardiometabolic variables (glucose, HbA1C, HOMA-IR, lipids, blood pressure), and biomarkers of inflammation, immune activation, and gut integrity quantified by ELISA. Patients were stratified into NOVA 4 groups based on the median and quartile proportions of total energy intake from NOVA 4 foods. Associations between dietary NOVA and outcomes were analyzed using generalized additive models (GAMs) adjusted for age, sex, race, and CD4 count. Results: Among 222 PWH (mean age 45.4 ± 14.2 years; 31% female; 66% non-white; BMI 30.61 ± 7.91 kg/m2), median NOVA 4 intake was 45.6% of total energy intake. Participants with higher vs. lower NOVA 4 intake showed differences in diet quality, but in GAMs, higher NOVA 4 intake was not associated with higher levels of inflammatory, cardiometabolic, gut integrity, and body composition variables. Conclusions: In PWH, UPF consumption was high but not associated with markers of cardiometabolic health, systemic inflammation, or gut integrity. This may reflect the multifactorial nature of the heightened inflammation in PWH, potentially obscuring the effect of diet.